MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vermillion Company Profile (NASDAQ:VRML)

Consensus Ratings for Vermillion (NASDAQ:VRML) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (108.33% upside)

Analysts' Ratings History for Vermillion (NASDAQ:VRML)
Show:
DateFirmActionRatingPrice TargetActions
5/18/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Vermillion (NASDAQ:VRML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/16/2016Q116($0.09)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016Q415($0.10)$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.10)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.08)($0.11)$1.50 million$535.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.10)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.08)($0.11)$1.59 million$1.57 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.10)$319.00 million$330.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.11)$0.32 million$0.23 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2013Q1 2013($0.15)($0.17)$0.30 million$0.33 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.21)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Vermillion (NASDAQ:VRML)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vermillion (NASDAQ:VRML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/28/2016Jack W SchulerMajor ShareholderBuy1,493$1.60$2,388.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016Jack W SchulerMajor ShareholderBuy3,700$1.57$5,809.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2016Jack W SchulerMajor ShareholderBuy30,700$1.46$44,822.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Jack W SchulerMajor ShareholderBuy57,749$1.45$83,736.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Jack W SchulerMajor ShareholderBuy8,400$1.56$13,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015Larry N FeinbergInsiderBuy512,043$1.96$1,003,604.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Jack W SchulerMajor ShareholderBuy1,288,339$1.44$1,855,208.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Larry N FeinbergInsiderBuy972,222$1.44$1,399,999.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014Peter S RoddyDirectorBuy16,502$1.44$23,762.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Valerie Barber PalmieriCOOBuy3,500$1.51$5,285.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014James T LafranceInsiderBuy27,907$1.44$40,186.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Valerie Barber PalmieriCOOBuy30,000$1.44$43,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014James T LafranceInsiderBuy41,615$1.43$59,509.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Eric SchoenCAOBuy5,000$1.42$7,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013William B CreechVPBuy2,000$2.33$4,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013William B CreechVPBuy10,000$3.18$31,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Vermillion (NASDAQ:VRML)
DateHeadline
06/22/16 03:07 PMVERMILLION, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 01:23 PMCroatia Launches Oil Exploration with 5 Blocks, $75M Investment -
06/07/16 04:49 PMETF’s with exposure to Vermillion, Inc. : June 7, 2016 -
06/03/16 10:04 AMVermillion, Inc. :VRML-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 -
02/16/16 08:00 AMVermillion Teams up With NASCAR Driver Martin Truex, Jr. and Partner Sherry Pollex, an Ovarian Cancer Thriver, to "Accelerate" the National Conversation about Ovarian Cancer and OVA1® - [PR Newswire] - AUSTIN, Texas, Feb. 16, 2016 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that NASCAR Sprint Cup Driver Martin Truex, Jr. and his longtime partner, Sherry Pollex, an ovarian cancer thriver, will be in the driver seats for the new OVA1® Awareness Team. Vermillion's OVA1® Awareness Team will ignite an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with use of the OVA1® blood test.
02/12/16 03:07 PMVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
02/11/16 08:00 AMVermillion's CPRIT-Sponsored Pelvic Mass Registry Steering Committee Chartered - [PR Newswire] - AUSTIN, Texas, Feb. 11, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the formation of the Steering Committee ...
02/09/16 08:00 AMVermillion Lands America's Most Decorated Gymnast and Ovarian Cancer Survivor, Shannon Miller, for its OVA1® Awareness Team - [PR Newswire] - AUSTIN, Texas, Feb. 9, 2016 /PRNewswire/ -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the most decorated gymnast in American history has joined its new OVA1 Awareness Team. As a member of Vermillion's Awareness Team, Shannon Miller will be tasked with "spring boarding" an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with the use of the OVA1 blood test. OVA1 is the first FDA-cleared blood test used to evaluate the cancer risk of a pelvic mass. Shannon is an ovarian cancer survivor, an accomplished author, an entrepreneur and a champion gymnast who has earned seven Olympic medals.
02/01/16 01:36 PMLatest Analysts Reports On Vermillion, Inc. (VRML) - Risers & Fallers - Latest Analysts Reports On Vermillion, Inc. (VRML)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Vermillion, Inc. (VRML). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 0 analysts “outperform”, 0 analysts “hold”, 0 analysts ...
01/21/16 12:40 PMA Major Shareholder at Vermillion (NASDAQ: VRML) is Buying Shares - Analyst Ratings - A Major Shareholder at Vermillion (NASDAQ: VRML) is Buying SharesAnalyst RatingsOver the last 3 months, the insider sentiment on Vermillion has been positive based on 17 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders. Vermillion Inc is engaged in discovery ...
01/20/16 12:26 PMAnalyst Coverage Updates - Vermillion, Inc. (VRML) - Risers & Fallers - Analyst Coverage Updates - Vermillion, Inc. (VRML)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Vermillion, Inc. (VRML). The latest broker reports which are currently outstanding on Wednesday 20th January state 1 analyst has a rating of “strong buy”, 0 analysts “buy ...
01/19/16 11:58 AMVermillion to Present at 7th Annual Life Science CEO Forum - CNNMoney - Vermillion to Present at 7th Annual Life Science CEO ForumCNNMoneyAUSTIN, Texas, Jan. 19, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7th Annual Life Science CEO Forum on January 25-26 in Atlanta ...
01/19/16 10:05 AMVermillion to Present at 7th Annual Life Science CEO Forum - [at noodls] - AUSTIN, Texas- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7 Annual Life Science CEO Forum on January ...
01/11/16 10:28 AMVermillion Exits 2015 with 33M Lives Covered for OVA1® - [at noodls] - AUSTIN, Texas - Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, exited 2015 with substantial coverage for its OVA1 diagnostic test, which helps physicians ...
01/11/16 05:54 AMVERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
01/04/16 03:14 PMVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
12/09/15 02:05 PMVermillion to Host Key Opinion Leader Meeting to Discuss Advances in Ovarian Cancer Detection - [at noodls] - Meeting and Live Webcast at 8am Eastern Time, December 11th AUSTIN, Texas, December 9, 2015 - Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced ...
12/08/15 12:17 PMVERMILLION, INC. Financials -
12/01/15 10:18 AMVermillion Announces Key Medical Policy Coverage by Medi-Cal for OVA1® Test - [at noodls] - AUSTIN, Texas, December 1, 2015 - Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced additional medical policy coverage for OVA1, with Medi-Cal, ...
11/17/15 09:33 AMVermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology & Diagnostics Forum - [at noodls] - AUSTIN, Texas, November 17, 2015 - Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive ...
11/12/15 08:56 AMVermillion Reports Third Quarter 2015 Financial Results and Business Update - [at noodls] - AUSTIN, Texas, Nov. 12, 2015- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported financial results for the third quarter ended September 30, 2015and ...
About Vermillion

Vermillion logoVermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VRML
  • CUSIP:
Key Metrics:
  • Previous Close: $1.24
  • 50 Day Moving Average: $1.24
  • 200 Day Moving Average: $1.46
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $62.54M
  • Current Quarter EPS Consensus Estimate: $-0.36 EPS
Additional Links:
Vermillion (NASDAQ:VRML) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha